Repligen (RGEN) Tops Q3 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $178.20 -0.04%
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Product revenue: 24.68M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.23, $0.07 better than the analyst estimate of $0.16. Revenue for the quarter came in at $141.2 million versus the consensus estimate of $140.67 million.
GUIDANCE:
Repligen sees FY2023 EPS of $1.70-$1.76, versus the consensus of $1.74. Repligen sees FY2023 revenue of $635-645 million, versus the consensus of $646 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ormat Technologies (ORA) Tops Q3 EPS by 27c; Offers Guidance
- Onterris, Inc. (ONT) Tops Q3 EPS by 48c
- Coty (COTY) Tops Q1 EPS by 3c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
